Trials / Completed
CompletedNCT01779206
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 4,936 (estimated)
- Sponsor
- West German Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin | |
| DRUG | Cyclophosphamide | |
| DRUG | Docetaxel | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2019-09-01
- Completion
- 2025-01-15
- First posted
- 2013-01-30
- Last updated
- 2025-04-08
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01779206. Inclusion in this directory is not an endorsement.